The prognostic role of 68Ga-PSMA11 PET-based response in prostate cancer patients undergoing taxane-based chemotherapy

Lukas Lunger; Maythinee Chantadisai; Amir Karimzadeh; Isabel Rauscher; Calogero D'Alessandria; Benedikt Feuerecker; Thomas Langbein; Robert Tauber; Stefan Schiele; Wolfgang Andreas Weber; Matthias Eiber

doi:10.2967/jnumed.122.264962

OtherTheranostics

The prognostic role of ⁶⁸Ga-PSMA11 PET-based response in prostate cancer patients undergoing taxane-based chemotherapy

Lukas Lunger, Maythinee Chantadisai, Amir Karimzadeh, Isabel Rauscher, Calogero D'Alessandria, Benedikt Feuerecker, Thomas Langbein, Robert Tauber, Stefan Schiele, Wolfgang Andreas Weber and Matthias Eiber

Journal of Nuclear Medicine December 2022, jnumed.122.264962; DOI: https://doi.org/10.2967/jnumed.122.264962

Lukas Lunger

1 Department of Urology, Rechts der Isar Medical Center, Technical University of Munich, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for Lukas Lunger

Maythinee Chantadisai

2 Division of Nuclear Medicine, Department of Radiology, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, The Thai Red Cross Society, Thailand;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for Maythinee Chantadisai

Amir Karimzadeh

3 Department of Nuclear Medicine, Rechts der Isar Medical Center, Technical University of Munich, Germany

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Isabel Rauscher

1 Department of Urology, Rechts der Isar Medical Center, Technical University of Munich, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Calogero D'Alessandria

3 Department of Nuclear Medicine, Rechts der Isar Medical Center, Technical University of Munich, Germany

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Benedikt Feuerecker

3 Department of Nuclear Medicine, Rechts der Isar Medical Center, Technical University of Munich, Germany

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Thomas Langbein

3 Department of Nuclear Medicine, Rechts der Isar Medical Center, Technical University of Munich, Germany

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Robert Tauber

1 Department of Urology, Rechts der Isar Medical Center, Technical University of Munich, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Stefan Schiele

1 Department of Urology, Rechts der Isar Medical Center, Technical University of Munich, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Wolfgang Andreas Weber

3 Department of Nuclear Medicine, Rechts der Isar Medical Center, Technical University of Munich, Germany

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for Wolfgang Andreas Weber

Matthias Eiber

3 Department of Nuclear Medicine, Rechts der Isar Medical Center, Technical University of Munich, Germany

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Supplemental
Info & Metrics
PDF

Data supplements

Supplemental Data

Files in this Data Supplement:

Supplemental Data

PreviousNext

In this issue

Journal of Nuclear Medicine

Vol. 66, Issue 3

March 1, 2025

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author
Complete Issue (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following The prognostic role of 68Ga-PSMA11 PET-based response in prostate cancer patients undergoing taxane-based chemotherapy

Message Subject (Your Name) has sent you a message from Journal of Nuclear Medicine

Message Body (Your Name) thought you would like to see the Journal of Nuclear Medicine web site.

Your Personal Message

Citation Tools

The prognostic role of ⁶⁸Ga-PSMA11 PET-based response in prostate cancer patients undergoing taxane-based chemotherapy

Journal of Nuclear Medicine Dec 2022, jnumed.122.264962; DOI: 10.2967/jnumed.122.264962

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

The prognostic role of ⁶⁸Ga-PSMA11 PET-based response in prostate cancer patients undergoing taxane-based chemotherapy

Journal of Nuclear Medicine Dec 2022, jnumed.122.264962; DOI: 10.2967/jnumed.122.264962

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Bookmark this article

User Name *

Password *

Remember my user name & password.

Jump to section

Article
Figures & Data
Supplemental
Info & Metrics
PDF

PubMed
Google Scholar

Cited By...

No citing articles found.

Google Scholar

Theranostics

¹⁷⁷Lu-Labeled Anticlaudin 6 Monoclonal Antibody for Targeted Therapy in Esophageal Cancer
Full-Body Tumor Response Heterogeneity of Metastatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radiopharmaceutical Therapy
Association of change in PSMA avid tumor burden during 177Lu-PSMA-617 therapy with overall survival: Should mid-point PET become standard protocol?

Show more Theranostics

Clinical (Oncology: GU)

Pretherapeutic Comparative Dosimetry of ¹⁷⁷Lu-rhPSMA-7.3 and ¹⁷⁷Lu-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer
A Comparison of ¹⁸F-DCFPyL, ¹⁸F-NaF, and ¹⁸F-FDG PET/CT in a Prospective Cohort of Men with Metastatic Prostate Cancer
Detection of Additional Primary Neoplasms on ¹⁸F-Fluciclovine PET/CT in Patients with Primary Prostate Cancer

Show more Clinical (Oncology: GU)

Keywords

oncology: GU
PET/CT
PET/MRI
68Ga-PSMA11 PET/CT
chemotherapy
metastatic prostate cancer
survival
treatment monitoring

Main menu

User menu

Search

The prognostic role of ⁶⁸Ga-PSMA11 PET-based response in prostate cancer patients undergoing taxane-based chemotherapy

Data supplements

Supplemental Data

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Theranostics

Clinical (Oncology: GU)

Similar Articles

Keywords